Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chiome BioscienceTSE:4583 -2.02%50 Days Inventory is 110.68 as of Jun. 2026, which is 13% above its 10-year median of 98.08. GuruFocus rates TSE:4583 with a GF Score™ of 50/100 and a GF Value™ of 円87.77 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 639 Biotechnology companies, Chiome Bioscience ranks better than 77.62% on this metric.
The historical rank and industry rank for Chiome Bioscience's Days Inventory or its related term are showing as below:
TSE:4583'
s Days Inventory Range Over the Past 10 Years
Min: 57.84 Med: 98.08 Max: 150.42
Current: 81.19
During the past 13 years, Chiome Bioscience's highest Days Inventory was 150.42. The lowest was 57.84. And the median was 98.08.
TSE:4583's Days Inventory is ranked better than 77.62% of 639
companies
in the Biotechnology industry
Industry Median: 184.66
vs TSE:4583: 81.19
Chiome Bioscience's Days Inventory
increased
from Jun. 2025 (78.71) to Jun. 2026 (110.68).
It might indicate that Chiome Bioscience's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Chiome Bioscience's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.82.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Chiome Bioscience's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.47.
Chiome Bioscience (TSE:4583) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Chiome Bioscience's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Chiome Bioscience's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Chiome Bioscience Days Inventory Related Terms
Chiome Bioscience Days Inventory Historical Data
* Premium members only.
The historical data trend for Chiome Bioscience's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4583 vs VRTX, REGN, MRNA: Days Inventory Comparison
For the Biotechnology subindustry, Chiome Bioscience's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiome Bioscience Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Days Inventory distribution charts can be found below:
* The bar in red indicates where Chiome Bioscience's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chiome Bioscience (TSE:4583) has a Days Inventory of 110.68 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Chiome Bioscience and its competitors. This is 13% above median its historical median of 98.08. Over the past decade, Chiome Bioscience's Days Inventory has ranged from 57.84 to 150.42. According to the industry distribution chart, Chiome Bioscience ranks #143 out of 639 companies in the Biotechnology industry, placing it in the top 22.4%.
Is Chiome Bioscience's Days Inventory too high?
Chiome Bioscience's current Days Inventory of 110.68 is 13% above median its 10-year median of 98.08. Over the past 10 years, this metric has ranged from a low of 57.84 to a high of 150.42. The Biotechnology industry median Days Inventory is 184.66. Chiome Bioscience's value of 110.68 is 40.1% below this industry median. Based on the distribution chart, Chiome Bioscience ranks #143 out of 639 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chiome Bioscience has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chiome Bioscience ranks #143 out of 639 companies for Days Inventory. This places Chiome Bioscience in the top 22% of its industry — outperforming the majority of peers. The industry median Days Inventory is 184.66. Chiome Bioscience's value of 110.68 is 40.1% below this benchmark. Historically, Chiome Bioscience's own Days Inventory has ranged from 57.84 to 150.42 over the past decade. While the company's 10-year median is 98.08 vs. the industry median of 184.66, Chiome Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.66, based on 639 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chiome Bioscience's current Days Inventory of 110.68 is 40.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Chiome Bioscience and its competitors. For the Biotechnology industry, the median Days Inventory is 184.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chiome Bioscience's current Days Inventory is 110.68, which is 13% above median its own 10-year median of 98.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Modestly Overvalued. The stock's GF Value™ is 円87.77, compared to a current price of 円97.00 — trading 10.5% above its estimated fair value. The current Days Inventory is 110.68, which is 13% above median its 10-year median of 98.08 and 40.1% below the Biotechnology industry median of 184.66. Chiome Bioscience's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Days Inventory is 110.68 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chiome Bioscience (TSE:4583) Overvalued in 2026?
Based on GuruFocus' analysis, Chiome Bioscience stock appears to be overvalued.
The current stock price of 円97.00 is trading 10.5% above its estimated GF Value™ of 円87.77.
GuruFocus considers Chiome Bioscience to be Modestly Overvalued.
Key valuation signals for TSE:4583:
Days Inventory: 110.68 (13% above median its 10-year median of 98.08)
GF Value™: 円87.77 vs. price of 円97.00 (10.5% above fair value)
Industry Position: 40.1% below the Biotechnology median (#143 of 639)
No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
50GF Score
Get the complete analysis for TSE:4583
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4583 has been successfully added to your 
